CDKN1A Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population that disrupts the CDKN1A gene in Raji B lymphocytes. This knockout model serves as a powerful tool for investigating p53-dependent cell cycle regulation and B-cell lymphoma biology by eliminating the cyclin-dependent kinase inhibitor p21, thereby removing a critical mediator of G1 arrest.
The Raji cell line is a well-characterized, Epstein-Barr virus (EBV)-positive B lymphocyte line derived from a human male with Burkitt lymphoma. Raji cells are widely employed in immunology and oncology research due to their transformed phenotype and susceptibility to EBV-driven signaling, making them an ideal host for examining tumor suppressor gene function and lymphocyte proliferation.
CDKN1A encodes p21, a potent inhibitor of cyclin-dependent kinases that enforces cell cycle arrest by binding to CDK2/cyclin E and CDK2/cyclin A complexes, blocking phosphorylation of RB1 and repressing E2F-mediated transcription. Activated by TP53 in response to DNA damage and modulated by upstream regulators such as TGF-??, FOXO3, and NF-??B, p21 also interacts with PCNA to inhibit DNA replication and engages in apoptosis regulation through interactions with caspase-3 and AKT.
In Raji cells, loss of CDKN1A function abrogates p53-mediated growth inhibition, unleashing unchecked proliferation and potentially exacerbating lymphomagenesis. The knockout background enables precise dissection of p21??s tumor-suppressive roles, including its contributions to senescence, apoptosis, and DNA damage checkpoint control, within a B-cell malignancy context relevant to Burkitt lymphoma and other lymphoproliferative disorders.
Researchers can utilize CDKN1A Knockout Raji Polyclonal Cells for studies of cell cycle progression, DNA damage response, apoptosis resistance, and p53 pathway dynamics. Common experimental workflows include flow cytometric cell cycle analysis, proliferation and apoptosis assays, Western blotting, RT-qPCR, and co-immunoprecipitation. This knockout model is especially suited for drug screening and functional genomics experiments targeting B-cell malignancies. For additional information, please contact Ascent Research.
